Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: dutton: we are raising our price target to $0.90 per share
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Funny, I thought they said, "and the four latest licenses' financial data will not be available until after the release of results for the quarter ended February 28, 2008. "

Don't know where you got mid '08 but April isn't that much sooner. LOL.

I don't know why bash Dutton. It's the companies fault for lack of visability. It's the companies fault for signing numbers only in 10-Q's. How about some acuracy here?

1 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply